Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of drugs in dermatology : JDD|
|State||Published - Jul 2007|
ASJC Scopus subject areas